The positive results from the double-blind period of the RISE UP Phase 2 study, which were presented at the 65 th American Society of Hematology (ASH) Annual Meeting & Exposition in December 2023, ...
Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer therapy, offering a 'magic bullet' strategy that combines the precision of monoclonal antibodies with the potency of ...
Despite global clinical trials increasing by 38% over the past decade, the European Economic Area’s (EEA) global share of trials has halved over the same period. A new report by IQVIA for EFPIA and ...
An invited Guest Editorial entitled “Give Cas a Chance,” by Fyodor Urnov, PhD, Director of Technology & Translation at the ...
Disruption is a pressing problem in the pharmaceutical world; patient health depends on clinical trial organisers avoiding it ...
FC Barcelona will provide the use of its medical facilities for the clinical trial phase of the project over the next few ...
AbbVie, a global, research-driven biopharmaceutical company, organized a visit to its R&D facilities—the AbbVie Cambridge ...
DelveInsight's Antibody-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...
A coalition of 12 Philadelphia-area health systems have abandoned the use of race adjustments in four clinical tools ...
BioNTech's Phase 3 NSCLC trial is paused after varying outcomes. Current participants continue treatment, and other trials ...
At the Neurocritical Care Society's (NCS) 22nd Annual Meeting this week, a University of Cincinnati researcher presented ...
The University of California, San Diego (UCSD) is actively seeking participants for five ongoing clinical trials focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback